Teva Agilect “Approvable” For Parkinson’s Disease
The company is pursuing an indication for rasagiline as monotherapy in early Parkinson’s disease and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease.
The company is pursuing an indication for rasagiline as monotherapy in early Parkinson’s disease and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease.